The German Lung Cancer Genomic Medicine National Network (nNGM) study (44) found that patients with co-existing KRAS and TP53 mutations are more likely to develop chemotherapy resistance, consistent with the patient’s case, suggesting the potential impact of genetic mutations on chemotherapy efficacy. Here, KRAS is linked to lung carcinoma.